Geron Corp.

How big is Geron Corp.?

As of Jun 18, Geron Corp. has a market capitalization of 923.53 million, with net sales of 116.29 million and a net profit of -139.02 million over the last four quarters.

Market Cap: As of Jun 18, Geron Corp. has a market capitalization of 923.53 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Geron Corp. reported net sales of 116.29 million and a net profit of -139.02 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 280.32 million and total assets of 594.46 million.

What does Geron Corp. do?

Geron Corporation is a late-stage clinical biopharmaceutical company focused on developing imetelstat for hematologic myeloid malignancies, with a market cap of approximately $923.53 million. As of March 2025, it reported net sales of $40 million and a net loss of $20 million.

Overview: <BR>Geron Corporation is a late-stage clinical biopharmaceutical company focused on the development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies, operating in the Pharmaceuticals & Biotechnology industry with a micro-cap market capitalization.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 40 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -20 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 923.53 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.57 <BR>Return on Equity: -51.19% <BR>Price to Book: 3.44<BR><BR>Contact Details: <BR>Address: 919 EAST HILLSDALE BOULEVARD, SUITE 250, FOSTER CITY CA: 94404 <BR>Tel: 1 650 4737700 <BR>Fax: 1 302 6365454 <BR>Website: http://www.geron.com

Should I buy, sell or hold Geron Corp.?

Who are in the management team of Geron Corp.?

As of March 2022, the management team of Geron Corp. includes Dr. John Scarlett as Chairman, President, and CEO, with Ms. Karin Eastham as Lead Independent Director and independent directors Ms. Dawn Bir, Dr. V. Bryan Lawlis, Dr. Susan Molineaux, and Ms. Elizabeth O'Farrell.

As of March 2022, the management team of Geron Corp. includes Dr. John Scarlett, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features Ms. Karin Eastham as the Lead Independent Director, along with independent directors Ms. Dawn Bir, Dr. V. Bryan Lawlis, Dr. Susan Molineaux, and Ms. Elizabeth O'Farrell.

Is Geron Corp. overvalued or undervalued?

As of August 8, 2024, Geron Corp. is rated as risky due to significant losses and negative return metrics, with key ratios indicating overvaluation compared to peers and a year-to-date stock performance of -62.71% versus the S&P 500's 12.22%.

As of 8 August 2024, the valuation grade for Geron Corp. has moved from does not qualify to risky, indicating a deterioration in its financial outlook. The company appears to be overvalued given its significant losses and negative return metrics. Key ratios include a Price to Book Value of 3.80, an EV to EBIT of -6.45, and an EV to EBITDA of -6.51, all of which suggest that the company's valuation is not supported by its financial performance.<BR><BR>In comparison to peers, Geron Corp. has a P/E ratio of -10.13, while Rhythm Pharmaceuticals, Inc. has a much steeper P/E of -36.41, and Aurinia Pharmaceuticals, Inc., which is rated fair, has a P/E of 20.87. The stark contrast in valuations highlights the challenges Geron Corp. faces in the market. Furthermore, the company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -62.71% compared to the index's 12.22%, reinforcing the notion that Geron Corp. is currently overvalued.

Is Geron Corp. technically bullish or bearish?

As of August 1, 2025, Geron Corp. shows a mildly bearish technical trend with mixed signals from MACD and RSI indicators, while significantly underperforming the S&P 500 with year-to-date returns of -62.71%.

As of 1 August 2025, the technical trend for Geron Corp. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish, indicating mixed signals. The RSI shows no signal on the weekly chart but is bullish on the monthly, suggesting potential upward momentum over a longer timeframe. However, the daily moving averages are bearish, and both the weekly Bollinger Bands and KST are mildly bearish. The Dow Theory indicates a mildly bearish stance on the weekly chart with no trend on the monthly.<BR><BR>In terms of performance, Geron Corp. has significantly underperformed compared to the S&P 500, with a year-to-date return of -62.71% versus the S&P's 12.22%, and a one-year return of -70.8% compared to the S&P's 17.14%. Overall, the current technical stance is mildly bearish with some strength in the weekly MACD and monthly RSI, but overall performance remains weak.